Nabarro leads on GSK £37m CMA fine over anti-competitive deals

Nabarro has advised GlaxoSmithKline (GSK) on a £37m fine imposed by the competition regulator over allegations it illegally stifled the launch of a cheap rival drug.

Premium content

This article is only available to Premium subscribers of The Lawyer. A Premium subscription provides you with: Exclusive news / In-house interviews / Managing partner interviews / Latest panel reviews / Latest deals and cases / Long-form analysis of market trend / In-house appointments / The Lawyer archives

View our subscription options

Already have access? Sign in below

Having problems?

Contact us on +44 (0)20 7292 3723 | email:

If you are looking for our Jobs site, please click here